Cytokine release syndrome and immune effector cell‑associated neurotoxicity syndrome in a melanoma patient treated with adjuvant pembrolizumab

Wesley SF, Haggiagi A, Thakur KT and De Jager PL: Neurological immunotoxicity from cancer treatment. Int J Mol Sci. 22(6716)2021.PubMed/NCBI View Article : Google Scholar

Ceschi A, Noseda R, Palin K and Verhamme K: Immune checkpoint inhibitor-related cytokine release Syndrome: Analysis of WHO global pharmacovigilance database. Front Pharmacol. 11(557)2020.PubMed/NCBI View Article : Google Scholar

Liu LL, Skribek M, Harmenberg U and Gerling M: Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: Case report and systematic review of the literature. J Immunother Cancer. 11(e005841)2023.PubMed/NCBI View Article : Google Scholar

Hamida O, Karlsson F, Lundqvist A, Gerling M and Liu LL: Cytokine release syndrome after treatment with immune checkpoint inhibitors: An observational cohort study of 2672 patients from Karolinska University Hospital in Sweden. Oncoimmunology. 13(2372875)2024.PubMed/NCBI View Article : Google Scholar

Tay SH, Toh MMX, Thian YL, Vellayappan BA, Fairhurst AM, Chan YH, Aminkeng F, Bharwani LD, Huang Y, Mak A and Wong ASC: Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: A case series of 25 patients and review of the literature. Front Immunol. 13(807050)2022.PubMed/NCBI View Article : Google Scholar

Zhang Y, Wen X, OuYang Y, Hu Y, Fang X, Zhang J and Yuan Y: Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients-A case report and review of the literature. Heliyon. 10(e24380)2024.PubMed/NCBI View Article : Google Scholar

Tanaka T, Taoka M, Makimoto G, Ninomiya K, Higo H, Fujii M, Ichihara E, Ohashi K, Hotta K, Tabata M and Maeda Y: Severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in a man receiving immune checkpoint inhibitors for lung cancer: A case report. Intern Med. 63:1261–1267. 2024.PubMed/NCBI View Article : Google Scholar

Kennedy LB and Salama AKS: A review of cancer immunotherapy toxicity. CA Cancer J Clin. 70:86–104. 2020.PubMed/NCBI View Article : Google Scholar

Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J and Jordan K: ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28 (suppl_4):iv119–iv142. 2017.PubMed/NCBI View Article : Google Scholar

Puzanov I, Diab A, Abdallah K, Bingham CO III, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, et al: Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 5(95)2017.PubMed/NCBI View Article : Google Scholar

Tvedt THA, Vo AK, Bruserud Ø and Reikvam H: Cytokine release syndrome in the immunotherapy of hematological malignancies: The biology behind and possible clinical consequences. J Clin Med. 10(5190)2021.PubMed/NCBI View Article : Google Scholar

Wang J and Doran J: The many faces of cytokine release syndrome-related coagulopathy. Clin Hematol Int. 3:3–12. 2021.PubMed/NCBI View Article : Google Scholar

Morris EC, Neelapu SS, Giavridis T and Sadelain M: Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 22:85–96. 2022.PubMed/NCBI View Article : Google Scholar

Velasco R, Villagrán M, Jové M, Simó M, Vilariño N, Alemany M, Palmero R, Martínez-Villacampa MM, Nadal E and Bruna J: Encephalitis induced by immune checkpoint inhibitors: A systematic review. JAMA Neurol. 78:864–873. 2021.PubMed/NCBI View Article : Google Scholar

Siegler EL and Kenderian SS: Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: Insights into mechanisms and novel therapies. Front Immunol. 11(1973)2020.PubMed/NCBI View Article : Google Scholar

Rice J, Nagle S, Randall J and Hinson HE: Chimeric antigen receptor T cell-related neurotoxicity: Mechanisms, clinical presentation, and approach to treatment. Curr Treat Options Neurol. 21(40)2019.PubMed/NCBI View Article : Google Scholar

Si S and Teachey DT: Spotlight on tocilizumab in the treatment of CAR-T-Cell-induced cytokine release syndrome: Clinical evidence to date. Ther Clin Risk Manag. 16:705–714. 2020.PubMed/NCBI View Article : Google Scholar

Ohira J, Kawamoto M, Sugino Y and Kohara N: A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. Medicine (Baltimore). 99(e19741)2020.PubMed/NCBI View Article : Google Scholar

Das S and Johnson DB: Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 7(306)2019.PubMed/NCBI View Article : Google Scholar